SHENZHEN, China--(BUSINESS WIRE)--Tongjitang Chinese Medicines Company (NYSE: TCM) (“Tongjitang” or the “Company”), a vertically integrated and profitable specialty pharmaceutical company focusing on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine (“TCM”) in China, today announced that the Ministry of Science and Technology and the National Administration for the Protection of State Secrets of the People’s Republic of China have granted the Company national trade secret status for its flagship product, Xianling Gubao (“XLGB”).
